Herzuma, Biosimilar to Herceptin, Available in US for HER2-positive Breast Cancers
News
Herzuma, a biosimilar to Genentech‘s Herceptin (trastuzumab), is now available in the U.S. for the same indications as the reference therapy, including for the treatment of HER2-positive breast cancers and stomach cancers. The ... Read more